Table 2

Patient characteristics II

Patient
Timea
Intubated
PaO2b
Glcc
Heparin, IU/24 hours
NAd
DOBe
Steroidsf
Sedationg

1
30

10.2 (8.0)
13.3
10,000



L, H
2
42

13.6 (11.0)
8.3
22,000



L, H, Q
3
39
X
9.2 (7.6)
8.0
10,000


X
M, F
4
37

8.3 (8.3)
6.3
LMWH 5,000


X
P, M
5
30
X
11.3 (9.1)
9.6
15,000
18


P, M
6
39
X
16.2 (9.3)
5.3
10,000
14

X
P, Mi, M
7
29

11.5 (8.4)
6.5
20,000
7
300

None
8
42

8.6 (6.8)
5.3
20,000
11
400

M
9
48
X
13.4 (12.1)
6.9
10,000
26

X
Mi, M
10
46
X
15.0 (10.2)
7.0
LMWH 2,500
20

X
Mi, F, M
11
48
X
11.3 (8.6)
5.7
LMWH 5,000
18

X
P, M, R
12
42

18.5 (15.1)
7.6
15,000



P, M
13
25
X
19.2 (9.3)
4.8
LMWH 5,000



P, F
14
6

13.8 (12.0)
6.7
None


X
None
15
44

11.7 (11.6)
6.1
LMWH 5,000

300

M, H
16
26

11.8 (11.2)
6.8
LMWH 5,000



None

Patients 1 to 12: sepsis-associated delirium present; patients 13 to 16: no sepsis-associated delirium. aTime, time interval (hours) between admission to the intensive care unit and measurements. bPaO2, partial pressure of oxygen during measurement (lowest recorded value between admission to the intensive care unit and measurement). cGlc, blood glucose levels (mmol/L). dNA, noradrenaline: μg/minute during measurement. eDOB, dobutamine: μg/minute during measurement. fPatient 3: 3 × 100 mg hydrocortisone per 24 hours; patient 14: 25 mg methylprednisolone per day; all other patients: 4 × 50 mg hydrocortisone per 24 hours. gF, fentanyl; H, haloperidol; L, lorazepam; M, morphine; Mi, midazolam; P, propofol; Q, quetiapine; R, remifentanil. LMWH, low-molecular-weight heparin.

Pfister et al. Critical Care 2008 12:R63   doi:10.1186/cc6891